Amantadine use in the French prospective NS-Park cohort
Archive ouverte
Fabbri, Margherita | Rousseau, Vanessa | Corvol, Jean-Christophe | Sommet, Agnès | Tubach, Florence | De Rycke, Yann | Bertille, Nathalie | Selvarasa, Yajiththa | Carvalho, Stephanie | Chaigneau, Véronique | Brefel-Courbon, Christine | Ory-Magne, Fabienne | Tessier, Samuel | Tir, Melissa | Bereau, Matthieu | Meissner, Wassilios | Thiriez, Claire | Marques, Ana | Remy, Philippe | Schneider, Vincent | Moro, Elena | Defebvre, Luc | Houeto, Jean Luc | Prange, Stephane | Eusebio, Alexandre | Geny, Christian | Frismand, Solène | Damier, Philippe | Reuther, Caroline Giordana | Castelnovo, Giovanni | Benatru, Isabelle | de Maindreville, Anne Doe | Drapier, Sophie | Maltête, David | Lagha-Boukbiza, Ouhaid | Rascol, Olivier | Aubignat, Mickael | Magnin, Eloi | Burbaud, Pr Pierre | Guehl, Pr Dominique | Foubert-Samier, Alexandra | Laurens, Brice | Boraud, Thomas | Vergnet, Sylvain | Bendetowicz, David | Palpacuer, Thomas | Debilly, Bérengère | Derost, Philippe | Beal, Charlotte | Salhi, Hayet | Dormeuil, Alice | Petit, Aimée | Gravier, Alban | Dupont, Gwendoline | Garnier, Lucie | Fraix, Valérie | Castrioto, Anna | Meoni, Sara | Carriere, Nicolas | Danaila, Teodor | Laurencin, Chloé | Thobois, Stéphane | Azulay, Jean-Philippe | Fluchere, Frédérique | Charif, Mahmoud | Picot, Marie-Christine | Hopes, Lucie | Corbille, Anne-Gaelle | Rouaud, Tiphaine | Derkinderen, Pascal | Alecu, Cosmin | Heraud, Charlotte | de Verdal, Marie | Degos, Bertrand | Mangone, Graziella | Sambin, Sara | Lanore, Aymeric | Courtin, Thomas | Mariani, Louise-Laure | Khoury, Fouad | Menon, Poornima | Cormier-Dequaire, Florence | Flamand-Roze, Emmanuel | Grabli, David | Hainque, Elodie | Vidhaillet, Marie | Meneret, Aurélie | Delorme, Cécile | Foucard, Cendrine | von Raison, Florian | Elbaz, Alexis | Hartmann, Andreas | Leclercq, Vincent | Ansquer, Solène | Leh, Frederique | Leclercq, Marion | Costentin, Guillaume | Brefel Courbon, Christine | Leung, Clemence | Catala, Hélène | Causel, Astrid | Gaiffe, Emilie | Dupouy, Sandrine | Villars, Sandrine | Lai, Wei-Ho | Bari, Rachida | Chevanne, Damien | Durand, Elodie | Rieu, Isabelle | Bernard, Stephane | Garsault, Corinne | Boudjema, Noel | Grebent, Pascale | Kistner, Andrea | Pelissier, Pierre | Santraine, Valérie | Gaudin, Thomas | Boutet, Pierre | Caire, Catherine | Nouira, Manel | Verna, Claudia | Jardel, Amory | Puisieux, Salomé | Clement, Guillemette | Le Monnier, Lili | Frenais, Régis | Le Dily, Séverine | Chaigneau, Rachel | Ferrier, Vanessa | David, Elodie | Fra, Leslie | Foucaran, Elsa | Dongmo-Kenfack, Carole | Beauzor, Florence | Le, Mickael | Messar, Sonia | Liot, Sophie | Rabois, Emilie | Bonnaire-Verdier, Margaux | Kestens, Françoise | Gourhan, Rozenn | Lopez-Alfaro, Sandra | Houvenaghel, Jean-François | Alexandre, Mélanie | Bourdonnais, Christine | Vernon, Linda | Boumediene, Ahmed | Julie, Céline | Lobstein, Aurette | Longato, Nadine | Mitterle, Marie-Pierre | Philips, Clélie | Rummel, Hugo | Bras, Stéphanie | Harroch, Estelle | Gillet, Claudia
Edité par
CCSD ; Springer Verlag -
International audience.
Objective: To assess amantadine use and associated factors in the patients with Parkinson's disease (PD).Background: Immediate-release amantadine is approved for the treatment of PD and is largely used in clinical practice to treat "levodopa-induced dyskinesia (LIDs). Its use varies according to countries and PD stages. The prospective NS-Park cohort collects features of PD patients followed by 26 French PD Expert Centres.Methods: Variables used for the analyses included demographics, motor and non-motor PD symptoms and motor complications [motor fluctuations (MFs), LIDs)], antiparkinsonian pharmacological classes and levodopa equivalent daily dose (LEDD). We evaluated: (i) prevalence of amantadine use and compared clinical features of amantadine users vs. non-users (cross-sectional analysis); (ii) factors associated with amantadine initiation (longitudinal analysis); (iii) amantadine effect on LIDs, MFs, apathy, impulse control disorders and freezing of gait (Fog) (longitudinal analysis).Results: Amantadine use prevalence was 12.6% (1,585/12,542, median dose = 200 mg). Amantadine users were significantly younger, with longer and more severe PD symptoms, greater LEDD and more frequent use of device-aided/surgical treatment. Factors independently associated with amantadine initiation were younger age, longer PD duration, more frequent LIDs, MFs and FoG, higher LEDD and better cognitive function. 9 of the 658 patients on amantadine had stopped it at the following visit, after 12-18 months (1.3%). New users of amantadine presented a higher improvement in LIDs and MF compared to amantadine never users.Conclusions: About 12% of PD patients within the French NS-Park cohort used amantadine, mostly those with younger age and more severe PD. Amantadine initiation was associated with a subsequent reduction in LIDs and MFs.
